Pulmonary arterial hypertension: Screening challenges in systemic sclerosis and future directions

European Respiratory Journal

Volumn 49, Issue 5, 2017, Pages

  Diab, Nermin ^a   Hassoun, Paul M ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ALGORITHM; COHORT ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; FOOD AND DRUG ADMINISTRATION; HEART CATHETERIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; LUNG ARTERY PRESSURE; LUNG DIFFUSION CAPACITY; POST HOC ANALYSIS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; SIX MINUTE WALK TEST; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TIME TO TREATMENT; TRANSTHORACIC ECHOCARDIOGRAPHY;

FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; HYPERTENSION, PULMONARY; SCLERODERMA, SYSTEMIC;

EID: 85019085337     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00522-2017     Document Type: Review

References (15)

1. Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest 2012; 142: 448-456.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944.
3. Hinchcliff M, Fischer A, Schiopu E, et al. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 2011; 38: 2172-2179.
4. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.
5. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903-975.
6. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-1349.
7. Vandecasteele E, Drieghe B, Melsens K, et al. Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. Eur Respir J 2017; 49: 1602275.
8. Fisher MR, Criner GJ, Fishman AP, et al. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30: 914-921.
9. Gladue H, Steen V, Allanore Y, et al. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. J Rheumatol 2013; 40: 1706-1711.
10. Bae S, Saggar R, Bolster MB, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335-1342.
11. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340.
12. Humbert M, Coghlan JG, Ghofrani HA, et al. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum Dis 2017; 76: 422-426.
13. Galiè N, Barberà JA, Frost AE, et al. Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. N Engl J Med 2015; 373: 834-844.
14. Coghlan JG, Galiè N, Barberà JA, et al. Initial combination therapy with Ambrisentan and Tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis 2016; in press [https://doi.org/10.1136/annrheumdis-2016-210236].
15. Grünig E, Peacock AJ. Imaging the heart in pulmonary hypertension: an update. Eur Respir Rev 2015; 24: 653-664.